Authors : Swati Tewari, Swati Tewari, Alok Kumar, Alok Kumar, Ekta Rani, Ekta Rani
DOI : 10.18231/j.ijmr.2020.041
Volume : 7
Issue : 3
Year : 2020
Page No : 226-229
Introduction: Pseudomonas aeruginosa an opportunistic nosocomial pathogen, its increasing resistance to
broad-spectrum beta-lactams, mediated by extended-spectrum betalactamase enzymes (ESBL), is problem
worldwide. The present study was undertaken to determine the prevalence of ESBL-production among the
clinical isolates of Pseudomonas aeruginosa.
Materials and Methods: Various clinical specimens received in our laboratory were processed and
Pseudomonas aeruginosa was identified as per standard microbiological procedure. All isolates were
subjected for ESBL screening test. Potential ESBL producer was then subjected for ESBL Phenotypic
confirmatory test –Disc Diffusion method. Antimicrobial susceptibility test was performed by Kirby –
Bauer disc diffusion method on all confirmed isolates as per Clinical Laboratory Standard Institute (CLSI
2016) guidelines.
Results: A total of 322 non duplicate isolates of Pseudomonas aeruginosa identified during the study
period. Of these 26.09% (n = 84) of Pseudomonas aeruginosa isolates were found to be ESBL producers.
All ESBL positive Pseudomonas aeruginosa isolates showed high resistance to ciprofloxacin 79 (94.05%),
Gentamicin 61 (72.62%) and tobramycin 60 (71.43%). Resistance was low to drugs like cefoparazone +
salbactum 17 (20.24 %) and piperacillin + Tazobactum 14 (16.67%), and Imipenem 15 (17.86 %). All the
isolates showed 100% sensitive to Polymyxin B.
Conclusion: Present study highlights the prevalence and drug resistance of ESBL positive Pseudomonas
aeruginosa. Regular antimicrobial susceptibility monitoring is essential for judicial use of antibiotics in
order to prevent the spread of drug resistance.
Keywords: P. aeruginosa, β lactam, ESBL.